Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway

Blood

Volumn 105, Issue 3, 2005, Pages 1329-1336

  Soulier, Jean ^a   Leblanc, Thierry ^b   Larghero, Jérôme ^b   Dastot, Hélène ^b   Shimamura, Akiko ^b   Guardiola, Philippe ^b   Esperou, Hélène ^b   Ferry, Christèle ^b   Jubert, Charlotte ^b   Feugeas, Jean Paul ^b   Henri, Annie ^b   Toubert, Antoine ^b   Socié, Gérard ^b   Baruchel, André ^b   Sigaux, François ^b   D'Andrea, Alan D ^b   Gluckman, Eliane ^b  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP D2 PROTEIN; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; CHILD; CHROMOSOME BREAKAGE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FANCONI ANEMIA; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFANT; MAJOR CLINICAL STUDY; MALE; MOSAICISM; NEWBORN; PATIENT CODING; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; UBIQUITINATION;

EID: 19944431331     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-05-1852     Document Type: Article

References (43)

1. Alter BP. Inherited bone marrow failure syndromes. In: Nathan DG, Ginsburg D, Orkin SH, Look AT, eds. Hematology of Infancy and Childhood. Vol 1. 6th ed. Philadelphia, PA: Saunders; 2003:280-363.
2. Auerbach AD, Buchwald M, Joenje H. Fanconi anemia. In: Scriver CR, ed. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:753-768.
3. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2:446-457.
4. Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for two new genetic subtypes. Blood. 2003;103:2498-2503.
5. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature. 1992;356:763-767.
6. Timmers C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell. 2001;7:241-248.
7. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606-609.
8. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003;35:165-170.
9. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23-34.
10. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001;7:249-262.
11. Nakanishi K, Taniguchi T, Ranganathan V, et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol. 2002;4:913-920.
12. Hussain S, Wilson JB, Medhurst AL, et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet. 2004;13:1241-1248.
13. Wang X, Andreassen PR, D'Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol. 2004;24:5850-5862.
14. Taniguchi T, Garcia-Higuera I, Xu B, et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell. 2002;109:459-472.
15. Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J. 2004;23:1178-1187.
16. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 2004; 18:1958-1963.
17. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249-1256.
18. Rosenberg PS, Huang Y, Alter BP. Individualized risks of first adverse events in patients with Fanconi anemia. Blood. 2004;104:350-355.
19. Gillio AP, Verlander PC, Batish SD, Giampietro PF, Auerbach AD. Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. Blood. 1997;90:105-110.
20. Faivre L, Guardiola P, Lewis C, et al. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. European Fanconi Anemia Research Group. Blood. 2000;96:4064-4070.
21. Hirsch B, Shimamura A, Moreau L, et al. Biallelic BRCA2/FANCD1 mutations: association with spontaneous chromosomal instability and solid tumors of childhood. Blood. 2004;103:2554-2559.
22. Wagner JE, Tolar J, Levran O, et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood. 2004;103:3226-3229.
23. Lo Ten Foe JR, Kwee ML, Rooimans MA, et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet. 1997;5:137-148.
24. Waisfisz Q, Morgan NV, Savino M, et al. Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet. 1999;22:379-383.
25. Gregory JJ, Jr., Wagner JE, Verlander PC, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA. 2001;98:2532-2537.
26. Gross M, Hanenberg H, Lobitz S, et al. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res. 2002;98:126-135.
27. Kwee ML, Poll EH, van de Kamp JJ, de Koning H, Eriksson AW, Joenje H. Unusual response to bifunctional alkylating agents in a case of Fanconi anaemia. Hum Genet. 1983;64:384-387.
28. Arwert F, Kwee ML. Chromosomal breakage in response to cross-linking agents in the diagnostic of Fanconi anemia. In: Schroeder-Kurth TM, Auerbach AD, Obe G, eds. Fanconi Anemia: Clinical, Cytogenic, and Experimental Aspects. Heidelberg: Springer-Verlag; 1989:83-92.
29. Auerbach AD. International Fanconi Anemia Registry: first report. In: Schroeder-Kurth TM, Auerbach AD, Obe G, eds. Fanconi Anemia: Clinical, Cytogenic, and Experimental Aspects. Heidelberg: Springer-Verlag; 1989:3-12.
30. Joenje H, Arwert F, Kwee ML, Madan K, Hoehn H. Confounding factors in the diagnosis of Fanconi anaemia. Am J Med Genet. 1998;79:403-405.
31. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989;73:391-396.
32. Berger R, Le Coniat M, Gendron MC. Fanconi anemia. Chromosome breakage and cell cycle studies. Cancer Genet Cytogenet. 1993;69:13-16.
33. Seyschab H, Friedl R, Sun Y, et al. Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood. 1995;85:2233-2237.
34. Shimamura A, de Oca RM, Svenson JL, et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood. 2002;100:4649-4654.
35. Guardiola P, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood. 2000;95:422-429.
36. Auerbach AD, Wolman SR. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature. 1976;261:494-496.
37. Pulsipher M, Kupfer GM, Naf D, et al. Subtyping analysis of Fanconi anemia by immunoblotting and reiroviral gene transfer. Mol Med. 1998;4:468-479.
38. Larghero J, Marolleau JP, Soulier J, et al. Hematopoietic progenitor cell harvest and functionality in Fanconi anemia patiente [letter]. Blood. 2002;100:3051.
39. Leteurtre F, Li X, Guardiola P, Le Roux G, et al. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol. 1999;105:883-893.
40. Ikeda H, Matsushita M, Waisfisz Q, et al. Genetic reversion in an acute myelogetious leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res. 2003;63:2688-2694.
41. Lensch MW, Tischkowitz M, Christianson TA, et al. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelocenous leukemia. Blood. 2003;102:7-16.
42. Houghtaling S, Timmers C, Noll M, et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 2003;17:2021-2035.
43. Liu TX, Howlett NG, Deng M, et al. Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apcotosis. Dev Cell. 2003;5:903-914.